The patient was treated with anti-vascular endothelial growth factor (VEGF)every 2 months, six times in total (Regeneron Pharmaceuticals, Inc, Tarrytown, USA, intravitreal ziv-aflibercept 1.25 mg/0.05 ml) and alternating with corticosteroids intravitreal every 2 months, five times in total (Sooft s.p.a., Fermo, Italy, Vitreal S 0.1 ml) to prevent neovascular glaucoma and to reduce possible radiation-induced ocular inflammation [17-19]. Here, VEGFA is linked to neovascular glaucoma.